On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans

Angiogenesis

Volumn 1, Issue 1, 1997, Pages 45-54

  Sasisekharan, Ram ^a   Ernst, Steffen ^b   Venkataraman, Ganesh ^c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Angiogenesis; Dimerization; Extracellular matrix; Fibroblast growth factor; Heparan sulfate; Heparin; Receptor; Signal transduction

Indexed keywords

EID: 0002891925     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018318914258     Document Type: Review

References (66)

1. Lin CQ, Bissell M. Multi-faceted regulation of cell differentiation by extracellular matrix. FASEB J. 1993; 7, 737-743.
2. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333, 1757-1763.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86, 353-364.
4. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88, 277-285.
5. Hahnenberger R, Jakobson AM, Ansari A, et al. Low-sulphated oligosaccharides derived from heparan sulphate inhibit normal angiogenesis. Glycobiology 1993; 3, 567-573.
6. Lepri A, Benelli U, Bernardini N, et al. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol 1994; 10, 273-280.
7. Norrby K, Sorbo J. Heparain enhance angiogenesis by a systemic mode of action. Int J Exp Pathol 1992; 73, 147-155.
8. Sasisekharan R, Moses MA, Nugent MA, et al. Heparinase inhibits neovascularization. Proc Natl Acad Sci USA 1994; 91, 1524-1528.
9. Baird A, Böhlen P. Fibroblast growth factors. In: Sporn MB, Roberts AB (Eds), Peptide Growth Factors and their Receptors I. Berlin: Springer-Verlag 1990; 369-418.
10. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992; 59, 115-165.
11. Springer BA, Pantoliano MW, Barbera FA, et al. Identification and concerted function of two receptor binding sufaces on basic fibroblast growth factor required for mitogenesis. J Biol Chem 1994; 269, 26879-26884.
12. Thompson LD, Pantoliano MW, Springer BA. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 1994; 33, 3831-3840.
13. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993; 259, 1918-1921.
14. Givol D, Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992; 6, 3362-3369.
15. Ornitz DM, Xu J, Colvin JS, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996; 271, 15292-15297.
16. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60, 1-40.
17. Schlessinger J, Lax I, Lemon M. Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? Cell 1995; 83, 357-360.
18. Friesel RB, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995; 9, 919-925.
19. Kjellèn L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991; 60, 443-475.
20. Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8, 365-393.
21. Conrad HE. Structure of heparan sulfate and dermatan sulfate. Ann NY Acad Sci 1989 556, 18-28.
22. Lindahl U, Lidholt K, Spillmann D, Kjellén L. More to 'heparin' than anticoagulation. Thromb Res 1994 75, 1-32.
23. Bourin M-C, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289, 313-330.
24. Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994; 79, 1005-1013.
25. Iozzo RV, Murdoch AD. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 1996; 10, 598-614.
26. Ihrcke NS, Platt JL. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J Cell Physiol 1996; 168, 625-637.
27. Reiland J, Ott VL, Lebakken CS, Yeaman C, McCarthy J, Rapraeger AC. Pervandadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1. Biochem J 1996; 319, 39-47.
28. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986; 128, 475-484.
29. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 1988; 130, 393-400.
30. Vlodavsky I, Fuks Z, Ishai-Michaeli R. Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J Cell Biochem 1991; 45, 167-176.
31. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267, 10931-10934.
32. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz D M. Cell surface, heparin-like moleculaes are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64, 841-848.
33. Nugent MA, Edelman ER. Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperativity. Biochemistry 1992; 31, 8876-8883.
34. Pantoliano M, Horlick RA, Springer BA, et al. Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry 1994; 33, 10229-10248.
35. Heldin C-H. Dimerization of cell surface receptors in signal transduction. Cell 1995; 80: 213-223.
36. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 1992; 12, 240-247.
37. Mascarelli F, Fuhrmann G, Courtois Y. aFGF binding to low and high affinity receptors induces both aFGF and aFGF receptors dimerization. Growth Factors 1993; 8, 211-233.
38. Spivak-Kroizman T, Lemmon MA, Dikic I, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994; 79, 1015-1024.
39. Eriksson AE, Cousens LS, Weaver LH, Matthews BW. Three-dimensional structure of human basic fibroblast growth factor. Proc Natl Acad Sci USA 1991; 88, 3441-3445.
40. Zhu X, Komiya H, Chirino I A, et al. Three-dimensional structures of acidic and basic fibroblast growth factors. Science 1991; 251, 90-93.
41. Zhang J, Cousens LS, Barr PJ, Sprang SR. Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1β. Proc Natl Acad Sci USA 1991; 88, 3446-3450.
42. Ago H, Kitagawa Y, Fujishima A, Matsuura Y, Katsube Y. Crystal structure of basic fibroblast growth factor at 1.6 Å resolution. J Biochem 1991; 110, 360-363.
43. Zhu X, Hsu BT, Rees DC. Structural studies of the binding of the anti-ulcer drug sucrose octasulfate to acidic fibroblast growth factor. Structure 1993; 1, 27-34.
44. Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn C-M, Waksman G. FGF binding and FGF receptor activation by synthetic heparin-derived di- and trisaccharides. Science 1995; 268, 432-436.
45. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. Heparin structure and interactions with basic fibroblast growth factor. Science 1996; 271, 1116-1120.
46. Blaber M, DiSalvo J, Thomas KA. X-ray crystal structure of human acidic fibroblast growth factor. Biochemistry 1996; 35, 2086-2094.
47. Prestrelski SJ, Fox GM, Arakawa T. Binding of heparin to basic fibroblast growth factor induces a conformational change. Arch Biochem Biophys 1992; 293, 314-319.
48. Klagsbrun M, Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell 1991; 67 229-231.
49. Habuchi H, Suzuki S, Saito T, et al. Structure of a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor. Biochem J 1992; 285, 805-813.
50. Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 1992; 267, 10337-10341.
51. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC. Activating and inhibitory heparin sequences for FGF-2 (Basic FGF). J Biol Chem 1993; 268, 23906-23914.
52. Isihara M, Tyrrell DJ, Stauber GB, Brown S, Cousens LS, Stack RJ. Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem 1993; 268, 4675-4683.
53. Maccarana M, Casu B, Lindahl U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol Chem 1993; 268, 23898-23905.
54. Tyrrell DJ, Isihara M, Rao N, et al. Structure and affinity of a heparin-derived hexaccharide with high affinity for basic fibroblast growth factor. J Biol Chem 1993; 268, 4684-4689.
55. Rapraeger AC. The coordinated regulation of heparan sulfate, syndecans and cell behavior. Curr Opin Cell Biol 1993; 5, 844-853.
56. Venkataraman G, Sasisekharan V, Herr AB, et al. Preferential self-association of basic fibroblast growth factor is stabilized by heparin during receptor dimerization and activation. Proc Natl Acad Sci USA 1996; 93, 845-850.
57. Roghani M, Mansukhani A, Dell'Era P, et al. Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J Biol Chem 1994; 269, 3976-3984.
58. Fannon M, Nugent MA. Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J Biol Chem 1996; 271, 17949-17956.
59. Vlodavsky I, Miao H-Q, Medalion B, Danagher P, Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 1996; 15, 177-186.
60. Gailit J, Clark AF. Wound repair in the context of extracellular matrix. Curr Opin Cell Biol 1994; 6, 717-725.
61. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80, 179-185.
62. Nurcombe V, Ford MD, Wildschut JA, Bartlett PF. Developmental regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteoglycan. Science 1993; 260, 103-106.
63. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA. (Eds), The Molecular Basis of Cancer. Philadelphia: Saunders 1995: 206-232.
64. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1, 27-31.
65. Fan T-PD, Jaggar R, Bicknell R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995; 16, 57-66.
66. Nicholls A, Sharp KA, Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 1991; 11, 281-296.